CCM
FLNA

Coldstream Capital Management’s Filana Therapeutics FLNA Stock Holding History

Coldstream Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-291
Closed -$437 – 2923
2025
Q1 		$437 Buy
+291
New +$734 ﹤0.01% 3389

Other funds holding FLNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Coldstream Capital Management's FLNA Position: Q2 2025 in Review

Coldstream Capital Management sold out of Filana Therapeutics (FLNA) in Q2 2025, closing a stake of 291 shares — an estimated $437 sold.

Coldstream Capital Management first reported a position in FLNA in Q1 2025 and held it in 1 quarter. The position peaked at $437 in Q1 2025. 97 funds tracked by Wall St. Rank hold FLNA as of Q2 2025.

  • Coldstream Capital Management reported no remaining Filana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 291 Filana Therapeutics shares in Q2 2025, an estimated $437.
  • Coldstream Capital Management first reported a position in Filana Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Filana Therapeutics position peaked at $437 in Q1 2025.
  • 97 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.